OPEN END TURBO BULL - ROCHE GS Share Price

Certificat

DE000KH98SH0

Delayed Deutsche Boerse AG 08:19:08 21/05/2024 pm IST
2.65 EUR -5.02% Intraday chart for OPEN END TURBO BULL - ROCHE GS
Current month+136.44%
1 month+102.17%
Date Price Change
21/24/21 2.65 -5.02%
20/24/20 2.79 0.00%
17/24/17 2.79 +10.28%
16/24/16 2.53 +39.78%
15/24/15 1.81 +18.30%

Delayed Quote Deutsche Boerse AG

Last update May 21, 2024 at 08:19 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Citi Citi
WKN KH98SH
ISINDE000KH98SH0
Date issued 19/09/2023
Strike 210 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 5.07
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.16
Lowest since issue 0.41

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW